Dr Shiang (Max) Lim

Research Unit

Cardiac regeneration


Head, Cardiac Regeneration Laboratory

Professional Experience

2018        Chair of Conference and Awards Committee, Australasian Society for
                Stem Cell Research (ASSCR)
2018        Peer review panel member for the NHMRC Grant Review Working
2017-18  Specialist advisor to the Australia Therapeutic Goods Administration
2012        Principal Investigator and Head Cardiac Regeneration Group, O’Brien
                Institute Department, SVI
2010       Senior Research Officer, The O’Brien Institute, Australia
2010       Honorary fellow, Department of Surgery, University of Melbourne
2006-10  Post-doctoral fellow, The Hatter Cardiovascular Institute, UCL, UK
2005       PhD in Physiology and Pharmacology, University of Strathclyde, UK
2002       Master in Pharmacy, University of Strathclyde, UK


2016       European Society of Cardiology/FCVB travel award
2012       HBPRCA Young Investigator Award
2012       APSH Young Investigator Fellowship
2002      Overseas Research Scholarship

Research Interests

Cardiac repair and regeneration, stem cell cardiac differentiation and secretomes, cardiac tissue engineering and organoid model; roles of mitochondrial morphology in cell survival and cardiogenesis.

Selected Publications

  1. Kalkhoran SB, Kriston-Vizi J, Hernandez-Resendiz S, Crespo-Avilan GE, Rosdah AA, Lees JG, Da Costa JRS, Ling NXY, Holien JK, Samangouei P, Chinda K, Ping YE, Riquelme JA, Ketteler R, Yellon DM, Lim SY*, Hausenloy DJ*. Hydralazine protects the heart against acute ischemia/reperfusion injury by inhibiting Drp1-mediated mitochondrial fission. Cardiovasc Res. 2020 Jan 3 *joint senior authors
  2. Hernández D, Millard R, Kong AM, Burns O, Sivakumaran P, Shepherd RK, Dusting GJ, Lim SY.  A tissue engineering chamber for continuous pulsatile electrical stimulation of vascularised cardiac tissues in vivo. Bioelectricity. 2020 Sep.
  3. Kompa AR, Greening DW, Kong AM, McMillan PJ, Fang H, Saxena R, Wong RCB, Lees JG, Sivakumaran P, Newcomb AE, Tannous BA, Kos C, Mariana L, Loudovaris T, Hausenloy DJ, Lim SY. Sustained subcutaneous delivery of secretome of human cardiac stem cells promotes cardiac repair following myocardial infarction. Cardiovasc Res. 2020 Apr 6.
  4. Rosdah AA, Smiles WJ, Oakhill JS, Scott JW, Langendorff CG, Delbridge LMD, Holien JK, Lim SY. New perspectives on the role of Drp1 isoforms in regulating mitochondrial pathophysiology. Pharmacol. Ther. 2020:107594.
  5. Lees JG, Kong AM, Chen YC, Sivakumaran P, Hernández D, Pébay A, Harvey AJ, Gardner DK, Lim SY. Mitochondrial fusion by M1 promotes embryoid body cardiac differentiation of human pluripotent stem cells.  Stem Cells International. 2019:6380135.
  6. Hoque A, Sivakumaran P, Bond ST, Ling NXY, Kong AM, Scott J, Bandara N, Hernández D, Liu GS, Wong RCB, Ryan MT, Hausenloy DJ, Kemp BE, Oakhill JS, Drew BG, Pébay ALim SY. Mitochondrial fission protein Drp1 inhibition promotes cardiac mesodermal differentiation of human pluripotent stem cells. Cell Death Discov. 2018:4:39.
  7. Nie SWang XSivakumaran PChong MMWLiu XKarnezis TBandara NTakov KNowell CJWilcox SShambrook MHill AFHarris NCNewcomb AEStrappe PShayan RHernández DClarke JHanssen EDavidson SMDusting GJPébay AHo JWKWilliamson NLim SY. Biologically active constituents of the secretome of human W8B2+ cardiac stem cells. Sci Rep. 2018:8(1):1579.
  8. Rosdah AA, Holien J, Delbridge LMD, Dusting GJ, Lim SY. Mitochondrial fission – a drug target for cytoprotection or cytodestruction? Pharmacol. Res. Prespective. 2016:4(3):e00235.
  9. Hernández D, Millard R, Sivakumaran P, Wong RCB, Crombie DE, Hewitt AW, Liang H, Hung SSC, Pébay A, Shepherd RK, Dusting GJ, Lim SY. Electrical stimulation promotes cardiac differentiation of human induced pluripotent stem cells. Stem Cell Int. 2016:1718041.
  10. Zhang Y, Sivakumaran P, Newcomb AE, Hernandez D, Harris N, Khanabdali R, Liu GS, Kelly DJ, Pébay A, Hewitt AW, Boyle A, Harvey R, Morrison WA, Elliott DA, Dusting GJ, Lim SY. Cardiac repair with a novel population of mesenchymal stem cells resident in the human heart. Stem Cells. 2015:33:3100-13.
  11. Ong SG, Lee WH, Theodorou L, Jodo K, Lim SY, Shukla DH, Briston T, Kiriakidis S, Ashcroft M, Davidson SM, Maxwell PH, Yellon DM, Hausenloy DJ. HIF-1 reduces ischaemia-reperfusion injury in the heart by targeting the mitochondrial permeability transition pore. Cardiovasc. Res. 2014:104(1):24-36.
  12. Hsiao ST, Dilley RJ, Dusting GJ, Lim SY. Ischemic preconditioning for cell-based therapy and tissue engineering. Pharmacol. Ther. 2013:142(2):141-53.
  13. Lim SY, Hausenloy DJ. Remote ischemic conditioning: from bench to bedside. Front. Physiol. 2012:3:27.
  14. Lim SY, Hausenloy DJ, Arjun S, Price AN, Davidson SM, Lythgoe MF, Yellon DM. Mitochondria cyclophilin-D as a potential therapeutic target for post-myocardial infarction heart failure. J. Cell. Mol. Med. 2011:15(11):2443-51.
  15. Ong SB, Subrayan S, Lim SY, Yellon DM, Davison SM, Hausenloy DJ. Inhibiting mitochondrial fission protects the heart against ischemia reperfusion injury. Circulation. 2010:121(18): 2012-22.